Eur J Clin Pharmacol DOI 10.1007/s00228-014-1730-x
REVIEW ARTICLE
Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis Xu-Ping Yang & Dan Lai & Xiao-Yan Zhong & Hong-Ping Shen & Yi-Lan Huang
Received: 28 May 2014 / Accepted: 5 August 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose To assess the efficacy and safety of the novel sodium glucose co-transporter 2 (SGLT2) inhibitor—canagliflozin for type 2 diabetes (T2DM). Methods A search of Medline (1946–January 2014), Embase (1950–January 2014), and The Cochrane Library for randomized controlled trials of canagliflozin compared to placebo or active comparator in T2DM was performed. Clinical Trials website and unpublished U.S. Food and Drug Administration data were also searched. Results Ten trials including 6,701 patients were analyzed. Compared with placebo, canagliflozin produced absolute
Xuping Yang and Dan Lai are co-authors Electronic supplementary material The online version of this article (doi:10.1007/s00228-014-1730-x) contains supplementary material, which is available to authorized users. X.